Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer

NCT ID: NCT05974059

Last Updated: 2023-08-03

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-08-01
• Study Completion Date: 2024-08-01

Brief Summary

The efficacy and safety of combination with Cadonilimab and CapeOX Regimen for neoadjuvant treatment of resectable locally advanced adenocarcinoma of the gastro-esophageal junction.

Detailed Description

This study was a single arm, open-label, single-center clinical study to evaluate the efficacy and safety of combination with Cadonilimab and CapeOX Regimen for neoadjuvant treatment of resectable locally advanced adenocarcinoma of the gastro-esophageal junction.

Conditions

Locally Advanced Unresectable Gastric Adenocarcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cadonilimab

10 mg/kg, d1, Q3W;

Group Type: EXPERIMENTAL

Oxaliplatin

Intervention Type: DRUG

Preoperative treatment：130mg/m2，iv, 2h，d1，Q3W; Postoperative treatment：130mg/m2，iv, 2h，d1，Q3W;

Capecitabine

Intervention Type: DRUG

Preoperative treatment：1000 mg /m2, PO，bid d1-14，Q3W； Postoperative treatment：1000 mg /m2, PO，bid. d1-14，Q3W；

Cadonilimab

Intervention Type: DRUG

Cadonilimab 10 mg/kg, d1, Q3W

Interventions

Oxaliplatin

Preoperative treatment：130mg/m2，iv, 2h，d1，Q3W; Postoperative treatment：130mg/m2，iv, 2h，d1，Q3W;

Intervention Type: DRUG

Capecitabine

Preoperative treatment：1000 mg /m2, PO，bid d1-14，Q3W； Postoperative treatment：1000 mg /m2, PO，bid. d1-14，Q3W；

Intervention Type: DRUG

Cadonilimab

Cadonilimab 10 mg/kg, d1, Q3W

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female, 18 years ≤ age ≤ 75 years;

2. ECOG score 0-1;

3. Histologically confirmed gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction.

4. c stageII, III(T1-4a/N+ M0, T3-4a/N-M0, AJCC 8th edition of gastric cancer cTNM stage) were performed according to enhanced CT/MRI examination (combined with ultrasonic gastroscopy and diagnostic laparoscopy if necessary).

5. The study site and the operator can complete radical dissection of D2 lymph nodes (the number of examined lymph nodes must be at least 15 to ensure the operation quality), and R0 resection;

6. Physical condition and organ function allow for larger abdominal surgery;

7. It has adequate organ and bone marrow functions and is defined as follows:

1)Blood routine test: absolute neutrophil count (ANC) ≥1.5×109/L; Platelet count(PLT)≥100×109/L; Hemoglobin (HGB)≥9.0 g/dL; 2)Liver function: Total serum bilirubin (TBIL) ≤1.5×upper limit of normal (ULN) is required for patients without liver metastasis. alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5*ULN; 3)Renal function: creatinine clearance rate (Ccr)≥50 mL/min (calculated by Cockcroft/Gault formula); a Female: Ccr= (140-years) x Body Weight (kg) x 0.85 72 x serum creatinine (mg/dL) b Males: Ccr= (140-years) x Weight (kg) x 1.00 72 x serum creatinine (mg/dL) 4) Adequate coagulation, defined as international normalized ratio (INR) or prothrombin time (PT) ≤1.5 times ULN; If the subject is receiving anticoagulant therapy, as long as the PT is within the intended range of the anticoagulant; 8 Left ventricular ejection fraction (LVEF)≥50% confirmed by echocardiography; 9 Agree and be able to comply with the protocol during the study; 10 Provide written informed consent prior to entering study screening and the patient is aware that she can withdraw from the study at any time during the study without loss; 11 Consent to provide blood and histological specimens

Exclusion Criteria

1. Complication of upper gastrointestinal tract obstruction/hemorrhage or digestive dysfunction or malabsorption syndrome;

2. Concomitant severe uncontrolled concurrent infection or other serious uncontrolled concomitant disease, moderate or severe renal injury;

3. Prior anti-tumor therapy, including chemotherapy, radiotherapy, targeted therapy or immunotherapy;

4. Other malignancies (except basal or squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ or breast cancer) in the past 5 years;

5. Uncontrolled pleural effusion, pericardial effusion or ascites;

6. Serious cardiovascular disease such as symptomatic coronary heart disease, congestive heart failure ≥Grade II, uncontrolled arrhythmia, myocardial infarction within 12 months prior to enrollment;

7. Allergic reaction to the drugs used in this study;

8. Use of steroids or other systemic immunosuppressive therapy 14 days prior to enrollment;

9. Patients receiving study medication within 4 weeks prior to enrollment (participating in other clinical trials);

10. Active autoimmune diseases;

11. Medical history of primary immunodeficiency;

12. Immunosuppressive medications were used within 4 weeks prior to the first dose of study treatment, excluding nasal spray, inhaled or other local corticosteroids or physiological doses of systemic corticosteroids (i.e. not more than 10 mg/day prednisone or equivalent dose of other corticosteroids), or the use of hormones to prevent contrast agent allergy;

13. Receiving an attenuated live vaccine within 4 weeks prior to the first dose of study treatment or scheduled for the duration of the study;

14. Known active tuberculosis;

15. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation;

16. HIV antibody positive, active hepatitis B or hepatitis C (HBV, HCV);

17. Pregnant or lactating women;

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Tianjin Medical University Cancer Institute and Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Xuewei Ding, MD

Role: STUDY_DIRECTOR

Tianjin Cancer Hospital Airport Hospital

Locations

Xuewei Ding

Tianjin, Tianjin Municipality, China

Countries

China

Central Contacts

Xuewei Ding, MD

Role: CONTACT

xding@tmu.edu.cn

18622220158

Facility Contacts

Xuewei Ding, MD

Role: primary

xding@tmu.edu.cn

18622220158

Other Identifiers

AK104-IIT-C-N1-0036

Identifier Type: -

Identifier Source: org_study_id